Bristol Myers Squibb has axed the degrader-antibody conjugate it bought from Orum Therapeutics for $100 million, walking away from the asset after seeing phase 1 data.
Bristol Myers Squibb has axed the degrader-antibody conjugate it bought from Orum Therapeutics for $100 million, walking away from the asset after seeing phase 1 data.